Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Open Access
- 22 April 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 115 (16), 3304-3313
- https://doi.org/10.1182/blood-2009-07-233304
Abstract
ABT-737 is a small-molecule antagonist of BCL-2 currently under evaluation in clinical trials in the oral form of ABT-263. We anticipate that acquired resistance to this promising drug will inevitably arise. To study potential mechanisms of resistance to ABT-737, we derived resistant lines from initially sensitive OCI-Ly1 and SU-DHL-4 lymphoma cell lines via long-term exposure. Resistance was based in the mitochondria and not due to an inability of the drug to bind BCL-2. Resistant cells had increased levels of BFL-1 and/or MCL-1 proteins, which are not targeted by ABT-737. Proapoptotic BIM was displaced from BCL-2 by ABT-737 in both parental and resistant cells, but in resistant cells, BIM was sequestered by the additional BFL-1 and/or MCL-1. Decreasing MCL-1 levels with flavopiridol, PHA 767491, or shRNA restored sensitivity to ABT-737 resistant cells. MCL-1 was up-regulated not by protein stabilization but rather by increased transcript levels. Surprisingly, in addition to stable increases in MCL-1 transcript and protein in resistant cells, there was a dynamic increase within hours after ABT-737 treatment. BFL-1 protein and transcript levels in resistant cells were similarly dynamically up-regulated. This dynamic increase suggests a novel mechanism whereby modulation of antiapoptotic protein function communicates with nuclear transcriptional machinery.This publication has 43 references indexed in Scilit:
- MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterpartsThe Journal of cell biology, 2009
- Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteinsProceedings of the National Academy of Sciences of the United States of America, 2008
- Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or BakScience, 2007
- Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737JCI Insight, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBlood, 2006
- An Mll-Dependent Hox Program Drives Hematopoietic Progenitor ExpansionCurrent Biology, 2004
- Cell Death: Critical Control PointsCell, 2004
- In vivo localisation and stability of human Mcl‐1 using green fluorescent protein (GFP) fusion proteinsFEBS Letters, 2000
- Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18Cell, 1985